Clinical Trial Update: Phase I/IIa Study of AZD5335 as Monotherapy and Combination Therapy in Participants With Solid Tumors [Phase 1, Phase 2]

View source ↗

Summary

AZD5335 is being studied in Phase 1/2a as both a single-agent therapy and in combination therapy for solid tumors, with recruitment ongoing. The trial includes …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Endometrial Cancer
• Lung Adenocarcinoma
• Ovarian Cancer

Drugs mentioned

• AZD5335 (AZD5335)

Snippet

Sponsor: AstraZeneca | Conditions: Ovarian Cancer, Lung Adenocarcinoma | Phase 1, Phase 2 | Status: RECRUITING